AI Tokens
Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Enterprise Value to EBITDA (EV/EBITDA)

Microsoft Excel

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Illumina Inc., EBITDA calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Net income attributable to Illumina stockholders 656 1,002 826 726 463
Add: Net income attributable to noncontrolling interest — (12) (44) (48) (35)
Add: Income tax expense 200 128 112 365 133
Earnings before tax (EBT) 856 1,118 894 1,043 561
Add: Interest expense 49 52 57 37 33
Earnings before interest and tax (EBIT) 905 1,170 951 1,080 594
Add: Depreciation expense 156 151 140 110 90
Add: Amortization of intangible assets 31 37 39 46 51
Earnings before interest, tax, depreciation and amortization (EBITDA) 1,092 1,358 1,130 1,236 735

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).


The financial trajectory from 2016 to 2020 is characterized by a period of significant growth followed by a notable contraction in the final year. Profitability metrics peaked in 2019 across all measured indicators before experiencing a synchronized decline in 2020.

EBITDA Performance Trends
Earnings before interest, tax, depreciation and amortization grew substantially from 735 million US$ in 2016 to a peak of 1,358 million US$ in 2019. A sharp increase was observed between 2016 and 2017, where the value rose by approximately 68%. Although a slight dip occurred in 2018, the metric recovered to reach its highest point in 2019 before falling to 1,092 million US$ in 2020.
Operational Profitability and Depreciation
A consistent gap is maintained between EBITDA and EBIT, reflecting the impact of depreciation and amortization. This difference expanded from 141 million US$ in 2016 to 188 million US$ in 2019, suggesting an increase in the company's asset base or amortization requirements over time. The operational profitability, as measured by EBIT, mirrored the EBITDA trend, peaking at 1,170 million US$ in 2019.
Net Income and Bottom-Line Correlation
Net income attributable to stockholders exhibited a more linear growth pattern than EBITDA between 2016 and 2019, rising from 463 million US$ to 1,002 million US$. However, the decline in 2020 was more severe for net income, which dropped to 656 million US$, representing a more significant percentage decrease than that observed in the EBITDA figure for the same period.
Comparative Earnings Volatility
While EBT and EBIT showed relative stability between 2017 and 2019, the 2020 results indicate a broad compression of margins. The reduction in EBITDA from 1,358 million US$ to 1,092 million US$ suggests a decrease in core operational cash flow generation during the final year of the analyzed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Enterprise Value to EBITDA Ratio, Current

Illumina Inc., current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 61,504
Earnings before interest, tax, depreciation and amortization (EBITDA) 1,092
Valuation Ratio
EV/EBITDA 56.32
Benchmarks
EV/EBITDA, Competitors1
AbbVie Inc. 33.09
Amgen Inc. 17.60
Bristol-Myers Squibb Co. 10.65
Danaher Corp. 25.51
Eli Lilly & Co. 47.82
Gilead Sciences Inc. 16.86
Johnson & Johnson 16.70
Merck & Co. Inc. 14.28
Pfizer Inc. 13.43
Regeneron Pharmaceuticals Inc. 15.48
Thermo Fisher Scientific Inc. 25.08
Vertex Pharmaceuticals Inc. 27.77

Based on: 10-K (reporting date: 2020-12-31).

1 Click competitor name to see calculations.

If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.


Enterprise Value to EBITDA Ratio, Historical

Illumina Inc., historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2020 Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Dec 31, 2016
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 69,822 41,239 41,525 31,596 23,847
Earnings before interest, tax, depreciation and amortization (EBITDA)2 1,092 1,358 1,130 1,236 735
Valuation Ratio
EV/EBITDA3 63.94 30.37 36.75 25.56 32.43
Benchmarks
EV/EBITDA, Competitors4
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).

1 See details »

2 See details »

3 2020 Calculation
EV/EBITDA = EV ÷ EBITDA
= 69,822 ÷ 1,092 = 63.94

4 Click competitor name to see calculations.


The financial trajectory from 2016 to 2020 is characterized by a substantial expansion in enterprise value that significantly outpaced the growth of operational earnings, resulting in a sharp increase in the valuation multiple by the end of the period.

Enterprise Value (EV) Trends
A consistent upward trend in enterprise value is observed, rising from 23,847 million US$ in 2016 to 69,822 million US$ by 2020. The growth was relatively steady between 2016 and 2019, followed by a precipitous increase in 2020, where the value grew by approximately 69% in a single year.
EBITDA Performance
Earnings before interest, tax, depreciation, and amortization exhibited volatility over the five-year span. After an initial increase from 735 million US$ in 2016 to 1,236 million US$ in 2017, EBITDA experienced a slight contraction in 2018, recovered to a peak of 1,358 million US$ in 2019, and subsequently declined to 1,092 million US$ in 2020.
EV/EBITDA Multiple Analysis
The EV/EBITDA ratio demonstrates significant fluctuation, reflecting a decoupling of market valuation from operational cash flow. The ratio declined from 32.43 in 2016 to a low of 25.56 in 2017, before oscillating between 30.37 and 36.75 through 2019. A dramatic escalation occurred in 2020, with the ratio peaking at 63.94, more than doubling the previous year's multiple. This surge indicates that the market assigned a substantially higher premium to the enterprise relative to its EBITDA performance during the final year of the analyzed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?